What Happened?
Austin, TX-based Savara Pharmaceuticals Appointed Rob Neville as Chief Executive Officer
About the Company
Savara Inc. is an orphan lung disease company. Savara`s pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for PAP, and in Phase 2a development for NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of MRSA infection in cystic fibrosis. Savara`s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara`s management team has significant experience in orphan drug development and pulmonary medicine, in identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.
About the Person
Rob Neville is the CEO of Savara Pharma developing an inhaled vancomycin antibiotic for MRSA infection in Cystic Fibrosis (CF) patients
Info Source
Press Release
Short Profile